60 Degrees Pharmaceuticals, Inc Common Stock

Yahoo Finance • 3 days ago

60 Degrees Pharmaceuticals Announces 2025 Annual Results

FY 2025 net product revenues increased 65% to $1,005,000Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.(NASDAQ: SXTP; SXT... Full story

Yahoo Finance • 3 months ago

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosisData support theory among specialists that Babesia infection may prolong recovery times in... Full story

Yahoo Finance • 4 months ago

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet medical need are bet... Full story

Yahoo Finance • 5 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

Q3 2025 net product revenue increased 223% year-over-year to $438 thousandGross profit/(loss) decreased from $24 thousand to $(100) thousand WASHINGTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; S... Full story

Yahoo Finance • 6 months ago

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)Results obtained using highest sensitivity... Full story

Yahoo Finance • 6 months ago

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company was split between ILADEF and GLA to recognize the winning nameB-FREE, a Phase 2 trial, will comme... Full story

Yahoo Finance • 7 months ago

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announc... Full story

Yahoo Finance • 7 months ago

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed by Q2 2026Site has clinical expertise in infectious disease trials and access to a robust patient po... Full story

Yahoo Finance • 8 months ago

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model$1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (... Full story

Yahoo Finance • 9 months ago

60 Degrees Pharmaceuticals announces pricing of up to $10 million public offering

* 60 Degrees Pharmaceuticals (NASDAQ:SXTP [https://seekingalpha.com/symbol/SXTP]) announced on Tuesday the pricing of a public offering of 2.63 million shares of the company’s common stock and accompanying Series A-1 and Series A-2 warra... Full story

Yahoo Finance • 9 months ago

60 Degrees Pharma targets $245 million market for babesiosis treatment

WASHINGTON - 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) announced Tuesday it has determined the maximum commercial market for its drug ARAKODA (tafenoquine) for treatment of human babesiosis to be approximately 380,000 patients annuall... Full story

Yahoo Finance • 12 months ago

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) stands against other stocks that fall behind amid market optim... Full story

Yahoo Finance • 3 years ago

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19; Com... Full story

Yahoo Finance • 3 years ago

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Management investor presentation webcast available Monday 9/11, 7:00 AM ETAttendees may request 1 x 1 meetings with management at meetings@hcwco.com WASHINGTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals Inc. (“60P” o... Full story

Yahoo Finance • 3 years ago

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV

MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased... Full story

Yahoo Finance • 3 years ago

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode of action differentiated from standard... Full story

Yahoo Finance • 3 years ago

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individualsTafenoquine kills dormant liver stage of P. vivax p... Full story

Yahoo Finance • 3 years ago

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of disease progression, has been registered... Full story